Endothelial Function in a Sample Group of Patients From the ICARE Study
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00314379|
Recruitment Status : Completed
First Posted : April 13, 2006
Last Update Posted : January 22, 2009
|Condition or disease||Intervention/treatment||Phase|
|Cardiovascular Diseases||Drug: Vitamin E 400IU/day||Phase 2 Phase 3|
Fifty patients will be randomly sampled from the ICARE untreated cohort (registry) of diabetic patients with Hp2-2 phenotype which were not randomised to treatment under ICARE study. Patients will be randomised to either vitamin E 400 IU/d or Placebo upon sampling for EFI study.
The patients will be tested for endothelial function by a method of Post Ischemic Flow mediated Dilatation.
all patients will undergo a baseline Endothelial Function test and then start taking the study drug for 2 months. at the end of two months of therapy the patients will undergo a second endothelial function test, then therapy will be stopped for 2 weeks and a cross over will be performed for an additional 2 months of therapy which in the end the third and final endothelial function test will be done.
An interim Results analysis is set to be done once the first 20 patients completed the protocol. In case of significant differences between the groups, study principal investigators will decide about study completion.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||50 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||Vitamin E Treatment and Endothelial Function in Type 2 Diabetic Patients With Hp 2-2 Phenotype From the I CARE Study (EFI)|
|Study Start Date :||April 2006|
|Actual Study Completion Date :||December 2007|
- Endothelial function by a non-invasive method of FMD
- Predefined in the protocol submitted to the EC approved prior to study beginning and the Inform Consent Form signed by all study participants prior to study related procedures, serum was preserved for the analysis of oxidative and inflammatory markers.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00314379
|Rambam Medical Center|
|Principal Investigator:||Shany Blum, M.D. M.Sc.||Technion, Israel Institute of Technology|
|Principal Investigator:||Uzi Milman, M.D.||Clalit Health Services|
|Principal Investigator:||Chen Shapira, M.D.||Clalit Health Services|
|Principal Investigator:||Giris Jacob, M.D. Ph.D.||Rambam Health Care Campus|
|Principal Investigator:||Lior Dayan, M.D. M.Sc.||Rambam Health Care Campus|
|Principal Investigator:||Andrew P Levy, M.D. Ph.D.||Technion, Israel Institute of Technology|